Importance of creatinine clearance for drug dosing in nursing home residents

Renal Failure

Volumn 36, Issue 1, 2014, Pages 46-49

  Shah, Jignesh ^a   Fogel, Joshua ^b   Balsam, Leah ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Creatinine; Diabetes mellitus; Elderly; Metformin; Renal insufficiency

Indexed keywords

CREATININE; METFORMIN;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NURSING HOME PATIENT; PRIORITY JOURNAL;

AGED; BIOMARKERS, PHARMACOLOGICAL; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INPATIENTS; KIDNEY FUNCTION TESTS; MALE; METFORMIN; MIDDLE AGED; NURSING HOMES; RETROSPECTIVE STUDIES;

EID: 84889586276     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.831719     Document Type: Article

References (19)

1. National Kidney Foundation. National kidney foundation kidney disease outcomes quality initiative. Available at: http://www. kidney.org/professionals/ doqi/kdoqi/p5
2. Alessandra CB, Marion SA, Natália CM, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. CJASN. 2008;3(2):348-354.
3. Fried LF, Boudreau R, Lee JS, et al. Health, aging and body composition study. Kidney function as a predictor of loss of lean mass in older adults: health, aging and body composition study. J Am Geriatr Soc. 2007;55(10):1578- 1584.
4. CA Jones, GM McQuillan, JW Kusek, et al. Serum Creatinine Levels in the US Population: Third National Health and Nutrition Examination Survey; Epidemiology, Clinical Trials, and End-Stage Renal Disease and Minority Health Programs. Bethesda, MD: DKUHD, NIDDK, NIH; 1998.
5. Howlett HCS, Bailey CJ. A risk-benefit assessment of Metformin in type 2 diabetes mellitus. Drug Saf. 1999;20:489-503.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
7. Calabrese AT, Coley KC, DaPos SV, et al. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434-437.
8. Misbin RI, Green L, Stadel BV, et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338: 265-266.
9. Morley JE. Diabetes mellitus: new approaches to management. Clin Geriatrics. 1996;4:75-81.
10. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of Metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24(6):683-693.
11. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties. Ottawa: The Association; 2001.
12. Edelman SV. Prescribing oral antidiabetic agents: general considerations. Clin Diabetes. 1998;16:37-41.
13. Shaw JS, Wilmot RL, Kilpatrick ES. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med. 2007;24:1160-1163.
14. Lardinois CK. Type 2 diabetes: glycemic targets and oral therapies for older patients. Geriatrics. 1998;53(11):22-34.
15. Bell DSH. Prudent utilization of the presently available treatment modalities for type 2 diabetes. Endocrinologist. 1998;8:332-331.
16. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998;6:89-131.
17. Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int Urol Nephrol. 2008;40:411-417.
18. Robinson JD, Lupkiewicz SM, Palenik L, et al. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40(6):1016-1019.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.